{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:09:59Z","timestamp":1790208599594,"version":"4.1.0"},"reference-count":11,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2023,12,20]]},"DOI":"10.18632\/oncotarget.28543","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T13:49:31Z","timestamp":1703080171000},"page":"997-1008","source":"Crossref","is-referenced-by-count":7,"title":["The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies"],"prefix":"10.18632","volume":"14","author":[{"given":"Fusheng","family":"Zhou","sequence":"first","affiliation":[{"name":"GenFleet Therapeutics (Shanghai) Inc., Shanghai 201203, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Tang","sequence":"additional","affiliation":[{"name":"GenFleet Therapeutics (Shanghai) Inc., Shanghai 201203, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Le","sequence":"additional","affiliation":[{"name":"GenFleet Therapeutics (Shanghai) Inc., Shanghai 201203, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ge","sequence":"additional","affiliation":[{"name":"GenFleet Therapeutics (Shanghai) Inc., Shanghai 201203, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Cicic","sequence":"additional","affiliation":[{"name":"Sellas Life Sciences Group, New York, NY 10036, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubo","family":"Xie","sequence":"additional","affiliation":[{"name":"GenFleet Therapeutics (Shanghai) Inc., Shanghai 201203, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmin","family":"Ren","sequence":"additional","affiliation":[{"name":"GenFleet Therapeutics (Shanghai) Inc., Shanghai 201203, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Lan","sequence":"additional","affiliation":[{"name":"GenFleet Therapeutics (Shanghai) Inc., Shanghai 201203, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Lu","sequence":"additional","affiliation":[{"name":"GenFleet Therapeutics (Shanghai) Inc., Shanghai 201203, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.3390\/cancers13102497","article-title":"Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies-Current Understanding, (Pre-)Clinical Application and Promising Approaches","volume":"1","author":"Maletzki","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.3390\/cancers13092181","article-title":"Targeting CDK9 for Anti-Cancer Therapeutics","volume":"1","author":"Strebhardt","year":"2021","journal-title":"Cancers (Basel)"},{"key":"3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","article-title":"CDK9 inhibitors in acute myeloid leukemia","volume":"3","author":"Giordano","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.tcb.2014.10.006","article-title":"Taming of the beast: shaping Myc-dependent amplification","volume":"2","author":"Levens","year":"2015","journal-title":"Trends Cell Biol"},{"key":"5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","article-title":"Targeting transcription cycles in cancer","volume":"2","author":"Johnstone","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"6","doi-asserted-by":"publisher","first-page":"T211","DOI":"10.1530\/ERC-16-0299","article-title":"Targeting CDK9: a promising therapeutic opportunity in prostate cancer","volume":"2","author":"Wang","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"7","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3389\/fphar.2020.01230","article-title":"CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas","volume":"1","author":"Mai","year":"2020","journal-title":"Front Pharmacol"},{"key":"8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12032-021-01636-1","article-title":"CDK9 inhibitors in multiple myeloma: a review of progress and perspectives","volume":"3","author":"Szylberg","year":"2022","journal-title":"Med Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1016\/S2152-2650(22)00757-1","article-title":"Poster: AML-259 Pharmacokinetics and Bioequivalence of Two Formulations of GFH009 Maleate Injection in Sprague Dawley Rats","volume":"2","author":"Lu","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10","doi-asserted-by":"publisher","first-page":"9473","DOI":"10.1182\/blood-2022-159844","article-title":"First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed\/Refractory (r\/r) Hematologic Malignancies","volume":"14","author":"Wang","year":"2022","journal-title":"Presented at: 2022 Annual Meeting of the American Society of Hematology Meeting, New Orleans, LA"},{"key":"11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"2","author":"Reynolds","year":"1989","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T13:49:38Z","timestamp":1703080178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,20]]}},"alternative-id":["28543"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28543","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]}}}